Qureight has opened a second UK site in London as it expands its imaging operations and develops a 3D chest Foundation Model for clinical trials.

The Cambridge-based imaging company said the new Holborn site will support recruitment and development of its machine learning and data science teams following a $20 million Series B financing.

Qureight expands imaging and AI teams

Qureight provides imaging analysis and clinical trial services focused on lung and heart disease. The company said its workforce has increased from 15 to 60 employees over the past two years as demand for its imaging services has grown.

The new London site will house members of the company’s machine learning, data science, commercial and clinical operations teams alongside its existing Cambridge headquarters.

A major focus of the expansion will be development of Qureight’s 3D chest Foundation Model, which is intended to support the development of imaging biomarkers across a wider range of diseases.

The company currently uses compartment-specific CT biomarkers in fibrotic lung diseases. It plans to extend its imaging capabilities into areas including asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity.

Dr Muhunthan Thillai, co-founder and CEO of Qureight, said: “Establishing our second site in the UK accommodates expansion of our world-class team of ML engineers and data scientists. The development of our Foundation Model is key to enabling us to enter new markets and solidify our position as a leading imaging company.”

Foundation Model targets broader chest diseases

Foundation models are designed to learn patterns from large datasets and can subsequently be adapted for different applications.

For Qureight, the chest imaging model is intended to support the development of new imaging biomarkers without requiring each disease area to be approached entirely independently.

The company said this could help extend its existing imaging analysis capabilities into additional therapeutic areas and support the use of quantitative imaging in clinical trials.

The expansion also comes as biopharma companies increasingly use imaging-derived measures to assess disease progression and treatment response, particularly in conditions where conventional clinical measures may not fully capture changes in disease.

London expansion follows $20M financing

Qureight’s second site follows a $20 million Series B financing and comes as the company increases its support for clinical trials, including late-stage programmes.

Rebecca Simmons, chief operating officer at Qureight, said: “Opening Qureight’s new office in London is a significant milestone. We selected London as the location for our second site to access an extensive pool of machine learning, commercial and clinical operations talent, who will complement our incredible workforce based at our headquarters in Cambridge.”

The company said the London location will allow it to recruit additional specialist staff while maintaining its Cambridge base.

Its expansion reflects the growing role of AI and quantitative imaging in clinical development, particularly as drug developers seek more detailed measures of disease progression and treatment response.

For Qureight, the development of its chest Foundation Model is central to extending its imaging platform beyond its current focus and into a broader range of lung and heart diseases.